Whitepapers

This whitepaper from Innovative Rx Strategies examines the growing impact of GLP-1 medications—originally developed for diabetes but now widely used for obesity and other conditions—on US pharmacy benefit plans. It details the rapid expansion and projected market growth of GLP-1s, the significant clinical benefits and side effects, and the financial challenges posed by high drug costs and increasing demand. The report reviews new and pending FDA indications, emerging delivery forms, and strategies for managing the financial implications for health plan sponsors, such as restrictive coverage, utilization management, and alternative payment models. It also highlights the limited near-term relief from generics and the evolving landscape of direct-to-consumer cash programs. A central focus is on balancing access, cost, and long-term sustainability for employer health plans in the face of surging interest in GLP-1 therapies